Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
Novartis got a leg up on its competition Aug. 30 with an earlier-than-expected approval for Kymriah in pediatric ALL, ending the CAR-T pricing mystery with its $475,000 price tag, which the company is positioning as a relative bargain.
You may also be interested in...
Scrip spoke with global development head and chief medical officer John Tsai about the factors Novartis considers when it decides which R&D programs to advance, including externally sourced assets.
The response rate, with five complete responses, exceeds known responses to standard-of-care chemotherapy in heavily pre-treated folate receptor alpha-high patients. A US FDA filing is on track for early 2022.
New indication for second-line-plus acute lymphoblastic leukemia means Tecartus will compete with Novartis’s Kymriah, although the Gilead/Kite product is approved for older patient base.